Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million

Reuters

昨天

<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million

Lucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.
Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.
Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.
Net loss was USD 58.0 million.
Cash used in operations was USD 46.5 million.
Ended the year with cash on hand of USD 34.7 million.
Financing activities provided USD 59.0 million.
Business updates included an 18-month real-world analysis covering about 12,000 patients.
Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009805), on March 25, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2622400784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622400784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622400784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622400784","market":"us","top_or_hot":-1,"title":"Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Diagnostics published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.\n        </li>\n<li>\n          Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.\n        </li>\n<li>\n          Net loss was USD 58.0 million.\n        </li>\n<li>\n          Cash used in operations was USD 46.5 million.\n        </li>\n<li>\n          Ended the year with cash on hand of USD 34.7 million.\n        </li>\n<li>\n          Financing activities provided USD 59.0 million.\n        </li>\n<li>\n          Business updates included an 18-month real-world analysis covering about 12,000 patients.\n        </li>\n<li>\n          Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009805), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-26 04:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Diagnostics published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.\n        </li>\n<li>\n          Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.\n        </li>\n<li>\n          Net loss was USD 58.0 million.\n        </li>\n<li>\n          Cash used in operations was USD 46.5 million.\n        </li>\n<li>\n          Ended the year with cash on hand of USD 34.7 million.\n        </li>\n<li>\n          Financing activities provided USD 59.0 million.\n        </li>\n<li>\n          Business updates included an 18-month real-world analysis covering about 12,000 patients.\n        </li>\n<li>\n          Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009805), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LUCD","symbol_name":"LUCID DIAGNOSTICS INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2gf0bk:1","article_id":"2622400784","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622400784","pubTimestamp":1774472229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.Cash used in operations was USD 46.5 million.Ended the year with cash on hand of USD 34.7 million.Business updates included an 18-month real-world analysis covering about 12,000 patients.Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LUCD":"LUCID DIAGNOSTICS INC.","BK4082":"医疗保健设备","PAVM":"PAVmed Inc."},"translate_title":"Lucid Diagnostics 2025财年运营亏损扩大至5800万美元；收入增长9.3%至470万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LUCD":0.9,"PAVM":0.9},"content_text":"Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million\n    \n\n\nLucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.\n        \n\n          Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.\n        \n\n          Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.\n        \n\n          Net loss was USD 58.0 million.\n        \n\n          Cash used in operations was USD 46.5 million.\n        \n\n          Ended the year with cash on hand of USD 34.7 million.\n        \n\n          Financing activities provided USD 59.0 million.\n        \n\n          Business updates included an 18-month real-world analysis covering about 12,000 patients.\n        \n\n          Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009805), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}